Company Overview of Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal, and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in...
1801 Century Park East
Los Angeles, CA 90067
Founded in 2004
Key Executives for Ritter Pharmaceuticals, Inc.
Chief Executive Officer and Director
Founder, President and Director
Chairman and Chief Strategic Officer
Compensation as of Fiscal Year 2014.
Ritter Pharmaceuticals, Inc. Key Developments
Ritter Pharmaceuticals, Inc. Appoints Paul V. Maier as a Board of Directors
Apr 14 15
Ritter Pharmaceuticals, Inc. appointed Paul V. Maier as a Board of Directors. Mr. Maier will chair the company’s audit committee. Mr. Maier served for five years as the Chief Financial Officer of life sciences company Sequenom, Inc. He previously served for 15 years as the Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. Mr. Maier currently serves on the Boards of Directors of International Stem Cell Corporation, Apricus Biosciences, MabVax Therapeutics and Biological Dynamics.
Ritter Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Mar 23 15
Ritter Pharmaceuticals, Inc. filed its S-1 on Mar 23, 2015 for the period ending Dec 31, 2014. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Ritter Pharmaceuticals, Inc. Appoints Matthew W. Foehr to Board of Directors
Feb 9 15
Ritter Pharmaceuticals, Inc. announced the appointment of Matthew W. Foehr to the Board of Directors. Mr. Foehr is President and Chief Operating Officer of Ligand Pharmaceuticals and his appointment expands Ritter's Board membership to five Directors. He brings Ritter significant experience in many areas that are critical to business success, including clinical, operations and commercial. Mr. Foehr has more than 20 years of experience in the pharmaceutical industry, having managed global operations and various research and development programs.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 4, 2014